INTRODUCTION
Pseudomonas aeruginosa is a particularly problematic pathogen. As a nosocomial pathogen it causes the highest mortality rate of any other bacterium (7, 18, 52) . Bacteremia, pneumonia (11) , osteomyelitis, and endocarditis (68) due to P. aeruginosa have therapeutic failure and mortality rates notably higher than those for other bacterial pathogens.
On the other hand, there are numerous antibacterial agents with in vitro activity against P. aeruginosa. In addition, since the early 1980s, even more potent "antipseudomonal" antibiotics have been introduced (Table 1) .
However, there are a number of unresolved issues which render antibiotic selection for P. aeruginosa more complex than that for other pathogens. They include (i) lack of standardization of in vitro susceptibility and synergy testing, with subsequent variability of results; (ii) failure of in vitro susceptibility and synergy results to be able to be extrapolated to clinical efficacy; (iii) inconsistent therapeutic results of in vivo models of P. aeruginosa infections; and (iv) dearth of therapeutic studies with patients infected with P. aeruginosa which would address and resolve these issues.
This minireview will focus on the following selected issues regarding antipseudomonal antibiotic therapy: (i) historical overview; (ii) in vitro versus in vivo synergy results from animal models and human trials; (iii) combination antibiotic therapy versus monotherapy; (iv) double-beta-lactam agent therapy; and (v) approaches to specific Pseudomonas infections ( Table 2) .
Historical overview. Mortality rates for P. aeruginosa bacteremia ranged from 79 to 96% in the 1950s. Colistin (polymyxin E), commercially released in 1959, was the first antimicrobial agent with significant in vitro activity against P. aeruginosa. Unfortunately, therapeutic efficacy failed to match in vitro susceptibility, and colistin was subsequently replaced by less toxic and more efficacious agents (gentamicin and carbenicillin) in the 1960s.
Although gentamicin was active in vitro against P. aeruginosa, a 71% mortality rate was still found for bacteremic patients treated with gentamicin (38) . Dosing with adequate peak concentrations was found to be critical in curing disseminated infections (69) . Treatment with carbenicillin resulted in mortality rates as low as 15 to 20% in bacteremic patients (9) . However, it was not long before resistance of P. aeruginosa to carbenicillin emerged, compromising the efficacy of this drug in treating P. aeruginosa infections.
The pharmaceutical industry has responded with a host of antipseudomonal antibiotics with potent activity in vitro and clinical success in anecdotal reports or noncomparative studies. They include broad-spectrum cephalosporins (cefoperazone, cefsulodin, ceftazidime, cefepime, and cefpirome), extended-spectrum penicillins (ticarcillin, piperacillin, and azlocillin), monobactams (aztreonam), carbapenems (imipenem), and quinolones (ciprofloxacin) ( Table 1) . While the addition of P-lactamase inhibitors to extended-spectrum penicillins has expanded the antibacterial spectra of these agents (clavulanate-ticarcillin [Timentin] and tazobactam), antipseudomonal activity has improved only marginally. Prospective randomized clinical trials of therapeutic agents for Pseudomonas infections are few. Most clinical trials of antibiotic therapy involving P. aeruginosa have been done in febrile neutropenic patients, and the antibiotics evaluated have been used as empiric therapy. A review of these trials reveals a paucity of documented infections attributable to P. aeruginosa. Larger studies of Pseudomonas bacteremias (4, 6, 9) have proven valuable in defining the clinical syndrome, but uncertainties exist for antibiotic therapy recommendations, given the retrospective nature of the studies, the accrual of patients over long periods of time (3 to 10 years), the noncomparative evaluation of antibiotics, and differing outcome endpoints.
Synergy-in vitro and in vivo. In vitro susceptibility testing offers a biologic rationale for the screening of new antipseudomonal agents by pharmaceutical companies and is used by clinicians to guide the selection of antibiotic therapies. Standardization of in vitro dilution testing has been particularly problematic with P. aeruginosa; important variables include divalent cation contents of media (67, 93) and inoculum size (24, 63) . In fact, a correlation of clinical outcome with in vitro susceptibility testing has not been established (4, 27, 30, 36, 56) (i.e., patients infected by organisms resistant to an antipseudomonal antibiotic do not necessarily fare worse than those infected by susceptible organisms). Dilution testing generally uses twofold dilution increments, resulting in large increments between dilutions at higher concentrations and often leading to an imprecise definition of MICs (87) . This problem is magnified in checkerboard tests for synergy.
The definition of synergy is method dependent in that the checkerboard dilution and time kill curve methods do not correlate with each other (14, 15, 36, 80) . Synergy in vitro between beta-lactam agents and aminoglycosides may be less likely if either agent individually demonstrates highlevel resistance. Furthermore, synergy is unpredictable for different strains of P. aeruginosa and different antipseudomonal agents (34) . Correlations between in vitro synergy and in vivo efficacy have been found more often in neutropenic animal models (12) . A number of studies of gram-negative bacteremia have suggested (but not proved) that combination therapy which is synergistic in vitro is therapeutically superior to combination therapy which is not synergistic in vitro (2, 22, 48, 53) . However, few studies have focused only on P. aeruginosa infections (2, 15, 36) . In one retrospective study of 18 patients with P. aeruginosa bacteremia, a synergistic combination of carbenicillin plus an aminoglycoside (as determined by checkerboard testing) was successful in 83% (10 of 12), while nonsynergistic (additive) combination therapy was successful in 0% (0 of 6) (2). However, in two more recent studies, no improvement in outcome could be demonstrated for combinations that were synergistic versus those that were not (as determined by checkerboard testing) (15, 36) . It is important to note, however, that the precise use of the fractional inhibitory concentration index has not been stan-dardized and that other mathematical analyses of checkerboard testing may provide more meaningful results (e.g., focusing only on concentrations that are clinically achievable). Time kill curve results were somewhat more predictive of clinical outcome in one comparative study of checkerboard dilution versus time kill curve methods (36) . Combination therapy of beta-lactam plus aminoglycoside agents. The demonstration of in vitro synergy with antipseudomonal penicillin and aminoglycoside agents, the disappointing results of gentamicin monotherapy, and the potential for the development of resistance with carbenicillin prompted trials of combination antibiotic therapy for serious Pseudomonas infections. Studies in neutropenic animals with P. aeruginosa septicemia tended to show that combination antibiotic therapy with a beta-lactam agent and an aminoglycoside was superior to monotherapy (16, 41, 42, 57, 77) .
Comparative trials in humans have been less consistent, with some studies showing increased efficacy of combination therapy in Pseudomonas infections (46, 74) and other studies failing to show such efficacy (8, 9) .
In a prospective, observational study of 200 consecutive patients with P. aeruginosa bacteremia conducted from 1982 to 1986, Hilf et al. (36) found that combination therapy was significantly better than monotherapy in improving outcome. Piperacillin or ticarcillin combined with tobramycin or gentamicin was the most common combination used. In an EORTC trial of therapy of 26 neutropenic patients with P. aeruginosa bacteremia, ceftazidime plus amikacin for 9 days was superior to ceftazidime plus amikacin for 3 days (P = 0.06); the authors pointed out that 62.5% (5 of 8) of bacteremic patients in the 3-day treatment group experienced treatment failure after amikacin was discontinued (25) .
Rifampin has been shown to be synergistic in vitro with antipseudomonal penicillin and aminoglycosides against P. aeruginosa (80, 92) and to improve survival in a neutropenic mouse model of Pseudomonas bacteremia (79, 91) and has been used as successful therapy in a limited number of patients with refractory Pseudomonas infections (90) . A prospective randomized trial of an antipseudomonal betalactam plus an aminoglycoside with or without rifampin was conducted with 121 patients with Pseudomonas bacteremia (50) . Although bacteriologic cure was demonstrated significantly more frequently in patients randomized to the rifampin-containing regimen, survival was not statistically different.
Double-beta-lactam agent therapy. A combination of two antipseudomonal beta-lactam agents has also been evaluated as empiric therapy in febrile neutropenic hosts (21) . Advantages include fewer side effects attributable to the removal of the aminoglycoside, especially nephrotoxicity. Theoretical disadvantages of double-beta-lactam agent therapy include the absence of in vitro synergy that might be found with a beta-lactam agent combined with an aminoglycoside and the potential induction of P-lactamases that could inactivate one of the beta-lactam agents.
Emergence of resistance was seen in 40% (2 of 5) of cases of P. aeruginosa infection in one series (84) . Double-betalactam therapy has proven inferior to beta-lactam-aminoglycoside therapy in neutropenic rats infected with P. aeruginosa (43) .
There have been few clinical studies comparing double beta-lactam therapy consisting of two antipseudomonal agents with standard therapy consisting of an antipseudomonal beta-lactam agent plus an aminoglycoside. In two studies involving moxalactam plus piperacillin versus moxalactam plus amikacin, the response rates of P. aeruginosa infections were superior for the aminoglycoside-containing regimen, although the sample size was small (23, 84) . Thus, at the current time, double-beta-lactam agent therapy should be avoided if there is a high likelihood of P. aeruginosa infections.
APPROACHES TO SPECIFIC INFECTIONS
Endocarditis. Endocarditis caused by P. aeruginosa is most commonly associated with intravenous drug abuse. Antibiotic efficacy for this infection is compromised by the unusually large inocula of organisms found on the valves (106 to 109 CFU/ml), especially on the left side (40) .
High-dose aminoglycoside therapy (e.g., tobramycin at 8 mg/kg/day) combined with a beta-lactam agent (e.g., ticarcillin or azlocillin) has been used successfully in studies in Detroit (68, 71) . Renal function, audiograms, and serum aminoglycoside concentrations should be monitored, although nephrotoxicity has, surprisingly, not proven problematic (71) . Serum bactericidal titers have not proven useful for monitoring (68, 83) .
Mortality for right-sided endocarditis is about 20% in uncomplicated cases treated early with combined antibiotic and surgical therapy, although right-sided endocarditis has been treated successfully with antibiotic therapy alone. Reyes and Lerner have recommended tricuspid valvulectomy in the event of bacteriologic failure or recurrence (68) . For left-sided endocarditis, early removal of the affected valve is highly recommended (17, 49, 59, 68, 83) . The indication for aggressive surgery is even more urgent if the valve is a prosthetic valve. Mortality is still high in left-sided infections, 50 to 60%, even with combined antibiotic and surgical therapy, but is significantly lower than with antibiotic therapy alone (17, 83) .
Ciprofloxacin has been shown to be comparable or superior to beta-lactam (azlocillin or ceftazidime)-aminoglycoside combination therapy in a rabbit model of endocarditis (5, 32) . Oral ciprofloxacin (500 mg every 6 to 8 h) successfully suppressed bacteremia in two patients with P. aeruginosa endocarditis (19) . However, relapses occurred at 3.5 months in one case when the dosage was decreased and at 22 months in another case when the ciprofloxacin was discontinued. For organisms isolated from the vegetations, there was a modest 4to 10-fold increase in the ciprofloxacin MIC, compared with that for the original blood isolate. Rifampin (600 mg every 8 h) in combination with antipseu-domonal penicillin and tobramycin led to a short-term bacteriologic response in two patients with P. aeruginosa endocarditis refractory to double-antibiotic therapy (90) . Interestingly, despite the excellent in vitro activity of piperacillin, numerous failures have been reported, with the emergence of resistant organisms during therapy (40, 55, 68) . Likewise, moxalactam failures have been reported (66, 73) .
The efficacies of the broad-spectrum cephalosporin agents and imipenem remain to be established. Meningitis. P. aeruginosa rarely causes meningitis. Mortality is high, especially if it is an end result of bacteremia in an immunosuppressed host, underlying endocarditis, or spread from malignant external otitis. Cure is more likely if the meningitis results from neurosurgical procedures involving ventricular shunts, drains, or reservoirs.
Ceftazidime has evolved as the therapy of choice because of its in vitro activity and ability to penetrate cerebrospinal fluid (28) . The addition of an aminoglycoside can be theoretically justified on the basis of the concept of synergistic interaction or prevention of ceftazidime resistance. However, the poor penetration of aminoglycosides into cerebrospinal fluid may require intrathecal or intraventricular administration. Although combined therapy seems reasonable, the addition of an aminoglycoside does not appear to enhance efficacy, as noted in anecdoctal reports. Ciprofloxacin has been successfully used, as noted in anecdotal reports (37, 58, 75) . However, given the relatively low ratio of cerebrospinal fluid concentrations to MICs for P. aeruginosa (61) , ciprofloxacin usage should be confined to situations in which organisms are resistant to beta-lactam agents.
Pneumonia. P. aeruginosa is said to be the most common cause of nosocomial pneumonia in the United States (13) . Evaluation of therapy for Pseudomonas pneumonia is complicated by the unreliability of sputum cultures in the etiologic diagnosis of pneumonia, especially in hospitalized patients with extensive oropharyngeal colonization. The special issue of cystic fibrosis is beyond the scope of this discussion.
Potent antipseudomonal beta-lactam agents are the key agents, given the relatively marginal penetration of aminoglycosides into respiratory secretions. Nichols and Maki concluded on the basis of a retrospective review of the literature that the addition of an aminoglycoside to betalactam agent therapy offered no particular therapeutic advantages in patients with P. aeruginosa pneumonia; neutropenic patients and patients with cystic fibrosis were excluded from this analysis (64) . Emergence of beta-lactam resistance was documented even when a beta-lactam agent was combined with an aminoglycoside. On the other hand, in a prospective study of 28 patients with bacteremically confirmed Pseudomonas pneumonia, survival rates in patients receiving combination therapy consisting of a beta-lactam agent plus an aminoglycoside were significantly better than those in patients receiving monotherapy (mostly an aminoglycoside only) (36) .
Endotracheally administered aminoglycosides have been shown to improve bacteriologic and clinical outcomes in open studies of nosocomial pneumonia (47, 76, 78) . Brown et al. showed that endotracheally administered tobramycin led to significantly better bacteriologic eradication than placebo in a double-blind study of aerobic gram-negative pneumonia (41% involving P. aeruginosa); however, clinical outcome was unaffected (10) .
Ciprofloxacin appears to be comparable to ceftazidime for the therapy of Pseudomonas pneumonia, although the numbers of patients studied have been few (33, 44) . Quinolones VOL. 35, 1991 have not been found to be synergistic with beta-lactam agents or aminoglycosides in animal models of pneumonia (45) .
For bacteremic, immunosuppressed, or critically ill patients with Pseudomonas pneumonia, it is our opinion that combination therapy with an antipseudomonal beta-lactam agent plus an aminoglycoside would be prudent.
Osteomyelitis and septic arthritis. The most common clinical presentations of Pseudomonas bone and joint infections are hematogenous dissemination in intravenous drug abusers, spread from contiguous foci, or superinfection of existing osteomyelitis. Antibiotic therapy is adjunctive to surgical debridement, and combination antibiotic therapy with a beta-lactam and an aminoglycoside is the current standard. However, the quinolone agents, particularly ciprofloxacin, have proven efficacious in open studies (20, 31, 35, 54) . The accepted duration of therapy is prolonged (4 to 8 weeks).
Pseudomonas osteochondritis associated with puncture wounds has been successfully treated with shorter courses (39) .
The quinolones may play a major role in single-agent treatment of chronic osteomyelitis following a course of combination therapy when the prolonged duration of therapy makes oral agents desirable. The extent of emergence of resistant organisms will be the limiting factor for oral singleagent therapy (1, 3, 35) . Malignant external otitis, a recalcitrant form of Pseudomonas osteomyelitis, has been treated with impressive success by oral ciprofloxacin with and without rifampin (70, 72) .
Urinary tract infections. Upper urinary tract infections caused by P. aeruginosa should be treated with parenteral agents. Monotherapy is likely adequate, as determined on the basis of clinical experience and given the fact that most antibiotics are concentrated in the urine; however, there are no data which specifically address this point.
For cystitis caused by P. aeruginosa, oral carbenicillin has been the mainstay of therapy, although both ciprofloxacin and norfloxacin have been proven efficacious in open studies (60) . Oral ciprofloxacin has also been proven comparable to parenteral aminoglycosides in the therapy of complicated urinary tract infections, although the subsequent emergence of resistant organisms has been common (3, 26) .
Febrile neutropenic hosts. With the superior in vitro activity of the new beta-lactam agents, interest in monotherapy has been renewed (82) . Although it is controversial (82, 89) , there is evidence that monotherapy with imipenem or ceftazidime may be comparable to combination therapy with a beta-lactam plus an aminoglycoside as empiric therapy for febrile neutropenic cancer patients (9, 65, 81) . The critical point may well be the number of P. aeruginosa infections encountered in febrile neutropenic patients, since these would be the patients in whom failures might be anticipated (85) . However, the incidence of P. aeruginosa infections appears to be decreasing in this patient group.
Unfortunately, it is well established that maximal survival of disseminated P. aeruginosa infections with bacteremia requires early administration of antibiotic therapy (4, 6, 7, 36, 50) . Thus, the strategy of adding an aminoglycoside when P. aeruginosa is isolated following prior empiric administration of a single beta-lactam agent may prove to be inadequate given any delay. This issue requires further clarification. However, if P. aeruginosa infections continue to decline in frequency in febrile neutropenic patients and if antipseudomonal vaccines prove efficacious, further trials of monotherapy will be warranted.
SUMMARY
The recommendations suggested in this minireview must be regarded as tentative pending the performance of comparative studies. Until such studies are performed, however, the approaches suggested in this minireview seem reasonable.
